to-BBB to enter clinic with €4 million financing
This article was originally published in Scrip
Executive Summary
to-BBB, the private Dutch biotechnology company developing novel treatments for conditions such as brain cancer and neurodegenerative diseases using a proprietary brain delivery platform, is poised to move its lead compound into the clinic after raising €4 million in the first close of a Series B investment round.